mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials - PubMed (original) (raw)
Clinical Trial
. 2019 May 31;37(25):3326-3334.
doi: 10.1016/j.vaccine.2019.04.074. Epub 2019 May 10.
Rainard Fuhr 2, Igor Smolenov 3, Amilcar Mick Ribeiro 3, Lori Panther 4, Mike Watson 5, Joseph J Senn 6, Mike Smith 7, Ӧrn Almarsson 8, Hari S Pujar 9, Michael E Laska 3, James Thompson 10, Tal Zaks 11, Giuseppe Ciaramella 3
Affiliations
- PMID: 31079849
- DOI: 10.1016/j.vaccine.2019.04.074
Free article
Clinical Trial
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
Robert A Feldman et al. Vaccine. 2019.
Free article
Abstract
Background: We evaluated safety and immunogenicity of the first mRNA vaccines against potentially pandemic avian H10N8 and H7N9 influenza viruses.
Methods: Two randomized, placebo-controlled, double-blind, phase 1 clinical trials enrolled participants between December 2015 and August 2017 at single centers in Germany (H10N8) and USA (H7N9). Healthy adults (ages 18-64 years for H10N8 study; 18-49 years for H7N9 study) participated. Participants received vaccine or placebo in a 2-dose vaccination series 3 weeks apart. H10N8 intramuscular (IM) dose levels of 25, 50, 75, 100, and 400 µg and intradermal dose levels of 25 and 50 µg were evaluated. H7N9 IM 10-, 25-, and 50-µg dose levels were evaluated; 2-dose series 6 months apart was also evaluated. Primary endpoints were safety (adverse events) and tolerability. Secondary immunogenicity outcomes included humoral (hemagglutination inhibition [HAI], microneutralization [MN] assays) and cell-mediated responses (ELISPOT assay).
Results: H10N8 and H7N9 mRNA IM vaccines demonstrated favorable safety and reactogenicity profiles. No vaccine-related serious adverse event was reported. For H10N8 (N = 201), 100-µg IM dose induced HAI titers ≥ 1:40 in 100% and MN titers ≥ 1:20 in 87.0% of participants. The 25-µg intradermal dose induced HAI titers > 1:40 in 64.7% of participants compared to 34.5% of participants receiving the IM dose. For H7N9 (N = 156), IM doses of 10, 25, and 50 µg achieved HAI titers ≥ 1:40 in 36.0%, 96.3%, and 89.7% of participants, respectively. MN titers ≥ 1:20 were achieved by 100% in the 10- and 25-µg groups and 96.6% in the 50-µg group. Seroconversion rates were 78.3% (HAI) and 87.0% (MN) for H10N8 (100 µg IM) and 96.3% (HAI) and 100% (MN) in H7N9 (50 µg). Significant cell-mediated responses were not detected in either study.
Conclusions: The first mRNA vaccines against H10N8 and H7N9 influenza viruses were well tolerated and elicited robust humoral immune responses. ClinicalTrials.gov NCT03076385 and NCT03345043.
Keywords: Immunogenicity; Pandemic influenza; Safety; Vaccines; mRNA.
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Similar articles
- Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses.
Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, Laska ME, Smith M, Almarsson Ö, Thompson J, Ribeiro AM, Watson M, Zaks T, Ciaramella G. Bahl K, et al. Mol Ther. 2017 Jun 7;25(6):1316-1327. doi: 10.1016/j.ymthe.2017.03.035. Epub 2017 Apr 27. Mol Ther. 2017. PMID: 28457665 Free PMC article. - Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
Forster AH, Witham K, Depelsenaire ACI, Veitch M, Wells JW, Wheatley A, Pryor M, Lickliter JD, Francis B, Rockman S, Bodle J, Treasure P, Hickling J, Fernando GJP. Forster AH, et al. PLoS Med. 2020 Mar 17;17(3):e1003024. doi: 10.1371/journal.pmed.1003024. eCollection 2020 Mar. PLoS Med. 2020. PMID: 32181756 Free PMC article. Clinical Trial. - Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.
Winokur P, El Sahly HM, Mulligan MJ, Frey SE, Rupp R, Anderson EJ, Edwards KM, Bernstein DI, Schmader K, Jackson LA, Chen WH, Hill H, Bellamy A; DMID 13-0034 H7N9 Vaccine Study Group. Winokur P, et al. Vaccine. 2021 Feb 22;39(8):1339-1348. doi: 10.1016/j.vaccine.2020.11.051. Epub 2021 Jan 21. Vaccine. 2021. PMID: 33485646 Free PMC article. Clinical Trial. - mRNA vaccines against respiratory viruses.
Whitaker JA, Sahly HME, Healy CM. Whitaker JA, et al. Curr Opin Infect Dis. 2023 Oct 1;36(5):385-393. doi: 10.1097/QCO.0000000000000948. Epub 2023 Jul 18. Curr Opin Infect Dis. 2023. PMID: 37462930 Review. - A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events.
Marra F, Young F, Richardson K, Marra CA. Marra F, et al. Influenza Other Respir Viruses. 2013 Jul;7(4):584-603. doi: 10.1111/irv.12000. Epub 2012 Sep 13. Influenza Other Respir Viruses. 2013. PMID: 22974174 Free PMC article. Review.
Cited by
- Avian Influenza Virus A(H5Nx) and Prepandemic Candidate Vaccines: State of the Art.
Focosi D, Maggi F. Focosi D, et al. Int J Mol Sci. 2024 Aug 5;25(15):8550. doi: 10.3390/ijms25158550. Int J Mol Sci. 2024. PMID: 39126117 Free PMC article. Review. - A decavalent composite mRNA vaccine against both influenza and COVID-19.
Wang Y, Ma Q, Li M, Mai Q, Ma L, Zhang H, Zhong H, Mai K, Cheng N, Feng P, Guan P, Wu S, Zhang L, Dai J, Zhang B, Pan W, Yang Z. Wang Y, et al. mBio. 2024 Sep 11;15(9):e0066824. doi: 10.1128/mbio.00668-24. Epub 2024 Aug 6. mBio. 2024. PMID: 39105586 Free PMC article. - Advances in vaccine development for Chlamydia trachomatis.
Poston TB. Poston TB. Pathog Dis. 2024 Feb 7;82:ftae017. doi: 10.1093/femspd/ftae017. Pathog Dis. 2024. PMID: 39043447 Free PMC article. Review. - Biodistribution of lipid nanoparticle, eGFP mRNA and translated protein following subcutaneous administration in mouse.
Sandelius Å, Naseer H, Lindqvist J, Wilson A, Henderson N. Sandelius Å, et al. Bioanalysis. 2024;16(14):721-733. doi: 10.1080/17576180.2024.2360361. Epub 2024 Jun 28. Bioanalysis. 2024. PMID: 38940441 - Introduction to RNA Vaccines Post COVID-19.
Kramps T. Kramps T. Methods Mol Biol. 2024;2786:1-22. doi: 10.1007/978-1-0716-3770-8_1. Methods Mol Biol. 2024. PMID: 38814388 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical